409 - A Phase 3, Randomized, Modified Double-blind Study Demonstrates Immunological Superiority of High-Dose (HD) Over Standard-Dose (SD) Inactivated Influenza Vaccine (IIV) in Adults 50 Through 64 Years of Age

Presenting Author(s)

• 

  Rachna Gupta, MD, MPH, FIDSA

  Global Clinical Development Strategy Expert
  Sanofi
  Morristown, New Jersey, United States

  Slides

Co-Author(s)

• AH

  Ashley Huang, MS

  Sanofi
  Chengdu, Sichuan, China
• 

  Lisa Jackson, MD, MPH (she/her/hers)

  Senior Investigator
  Kaiser Permanente Washington Health Research Institute
  Seattle, WA, United States
• SP

  Stephanie Pepin, PhD

  Sanofi
  Marcy-L'' Etoile, Rhone-Alpes, France
• Tm

  Tamala mallet Moore, PhD

  Therapeutic Area Head
  Sanofi
  Swiftwater, Pennsylvania, United States
• RO

  Riyadh Obeng, PhD

  Therapeutic Area Head
  Sanofi
  New Jersey, New Jersey, United States
• BK

  Beth Kelly, PhD

  AstraZeneca
  Gaithersburg, Maryland, United States
• ID

  Iris DeBruijn, PhD

  Sanofi
  Amsterdam, Noord-Holland, Netherlands